Sujatha Venkataraman
Concepts (355)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 18 | 2025 | 215 | 2.840 |
Why?
| | Glioma | 13 | 2025 | 426 | 2.560 |
Why?
| | Cerebellar Neoplasms | 14 | 2025 | 177 | 2.330 |
Why?
| | Gene Expression Regulation, Neoplastic | 21 | 2025 | 1462 | 1.310 |
Why?
| | Proto-Oncogene Proteins c-myc | 5 | 2025 | 167 | 0.960 |
Why?
| | Cell Proliferation | 24 | 2025 | 2499 | 0.950 |
Why?
| | Nuclear Proteins | 7 | 2025 | 749 | 0.950 |
Why?
| | Cell Line, Tumor | 30 | 2025 | 3550 | 0.940 |
Why?
| | Superoxide Dismutase | 14 | 2016 | 301 | 0.930 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.910 |
Why?
| | Brain Neoplasms | 7 | 2025 | 1322 | 0.910 |
Why?
| | Rhabdoid Tumor | 5 | 2025 | 103 | 0.900 |
Why?
| | Radiation Tolerance | 6 | 2022 | 103 | 0.830 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 66 | 0.700 |
Why?
| | Cell Cycle Proteins | 8 | 2022 | 629 | 0.640 |
Why?
| | Antineoplastic Agents | 8 | 2025 | 2197 | 0.620 |
Why?
| | Reactive Oxygen Species | 9 | 2022 | 621 | 0.610 |
Why?
| | Apoptosis | 16 | 2025 | 2430 | 0.590 |
Why?
| | Teratoma | 4 | 2022 | 120 | 0.580 |
Why?
| | Neoplastic Stem Cells | 3 | 2025 | 412 | 0.540 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1524 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 930 | 0.480 |
Why?
| | Histones | 6 | 2025 | 670 | 0.480 |
Why?
| | Central Nervous System Neoplasms | 2 | 2023 | 174 | 0.470 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 623 | 0.450 |
Why?
| | Tumor Cells, Cultured | 10 | 2025 | 919 | 0.450 |
Why?
| | Ependymoma | 3 | 2025 | 176 | 0.440 |
Why?
| | MicroRNAs | 2 | 2012 | 701 | 0.440 |
Why?
| | Brain Stem Neoplasms | 3 | 2021 | 87 | 0.440 |
Why?
| | Superoxides | 5 | 2010 | 204 | 0.420 |
Why?
| | Pyrazoles | 7 | 2022 | 510 | 0.400 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2020 | 433 | 0.400 |
Why?
| | Mice | 21 | 2025 | 18365 | 0.390 |
Why?
| | Cellular Senescence | 3 | 2019 | 226 | 0.380 |
Why?
| | Cerebellum | 3 | 2012 | 223 | 0.370 |
Why?
| | SMARCB1 Protein | 2 | 2025 | 34 | 0.360 |
Why?
| | Chromatin | 4 | 2025 | 561 | 0.340 |
Why?
| | Prostatic Neoplasms | 3 | 2016 | 978 | 0.330 |
Why?
| | Repressor Proteins | 2 | 2012 | 437 | 0.320 |
Why?
| | Transcription Factors | 3 | 2023 | 1742 | 0.310 |
Why?
| | Intracellular Space | 1 | 2010 | 66 | 0.310 |
Why?
| | RNA, Messenger | 5 | 2014 | 2832 | 0.300 |
Why?
| | Aging | 1 | 2020 | 1966 | 0.300 |
Why?
| | Pyrimidines | 5 | 2017 | 533 | 0.300 |
Why?
| | Cell Survival | 8 | 2017 | 1098 | 0.300 |
Why?
| | Cell Cycle | 9 | 2017 | 597 | 0.300 |
Why?
| | Animals | 23 | 2025 | 38109 | 0.290 |
Why?
| | Biomarkers, Tumor | 4 | 2020 | 1322 | 0.290 |
Why?
| | Humans | 62 | 2025 | 144957 | 0.280 |
Why?
| | Mutation | 4 | 2025 | 4099 | 0.280 |
Why?
| | NF-kappa B | 3 | 2025 | 662 | 0.260 |
Why?
| | Hydrogen Peroxide | 8 | 2008 | 336 | 0.250 |
Why?
| | DNA Repair | 3 | 2025 | 256 | 0.230 |
Why?
| | Pyrimidinones | 4 | 2020 | 126 | 0.230 |
Why?
| | Blotting, Western | 6 | 2014 | 1187 | 0.230 |
Why?
| | Homologous Recombination | 1 | 2025 | 36 | 0.230 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2016 | 298 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 50 | 0.230 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2025 | 53 | 0.220 |
Why?
| | Azepines | 3 | 2019 | 107 | 0.220 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1141 | 0.210 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2016 | 758 | 0.210 |
Why?
| | Transcription, Genetic | 3 | 2025 | 1496 | 0.210 |
Why?
| | Infratentorial Neoplasms | 1 | 2025 | 71 | 0.210 |
Why?
| | Piperazines | 4 | 2025 | 381 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2014 | 341 | 0.200 |
Why?
| | Radiation | 2 | 2021 | 24 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 339 | 0.200 |
Why?
| | Radiation, Ionizing | 2 | 2022 | 87 | 0.200 |
Why?
| | Epigenomics | 2 | 2020 | 114 | 0.190 |
Why?
| | Fever | 1 | 2004 | 312 | 0.190 |
Why?
| | Protein Biosynthesis | 1 | 2025 | 458 | 0.190 |
Why?
| | Genes, myc | 2 | 2020 | 51 | 0.190 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2012 | 49 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 434 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 469 | 0.180 |
Why?
| | von Willebrand Diseases | 1 | 2022 | 28 | 0.180 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2025 | 43 | 0.180 |
Why?
| | Phthalazines | 2 | 2025 | 64 | 0.180 |
Why?
| | Child | 14 | 2025 | 22657 | 0.180 |
Why?
| | von Willebrand Factor | 1 | 2022 | 85 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.170 |
Why?
| | Cell Differentiation | 5 | 2025 | 2050 | 0.170 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.170 |
Why?
| | Receptor, trkB | 1 | 2021 | 36 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 241 | 0.160 |
Why?
| | Single-Cell Analysis | 2 | 2022 | 359 | 0.160 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 64 | 0.160 |
Why?
| | Mice, Nude | 3 | 2020 | 688 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 33 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2020 | 45 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.150 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 280 | 0.150 |
Why?
| | RNA, Small Interfering | 4 | 2022 | 635 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 82 | 0.150 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.150 |
Why?
| | Astrocytoma | 1 | 2020 | 129 | 0.150 |
Why?
| | Free Radicals | 4 | 2009 | 110 | 0.150 |
Why?
| | Karyopherins | 1 | 2019 | 20 | 0.150 |
Why?
| | Catalase | 4 | 2008 | 130 | 0.150 |
Why?
| | Pteridines | 2 | 2016 | 22 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2020 | 221 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 496 | 0.140 |
Why?
| | Lysine | 1 | 2020 | 302 | 0.140 |
Why?
| | Sulfonamides | 1 | 2022 | 581 | 0.140 |
Why?
| | Enzyme Inhibitors | 4 | 2020 | 826 | 0.130 |
Why?
| | Promoter Regions, Genetic | 5 | 2017 | 1258 | 0.130 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 210 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 531 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2014 | 1786 | 0.130 |
Why?
| | Child, Preschool | 7 | 2021 | 11799 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.130 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 19 | 0.130 |
Why?
| | Cisplatin | 2 | 2016 | 334 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 129 | 0.130 |
Why?
| | Triazoles | 2 | 2019 | 184 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Glioblastoma | 1 | 2020 | 353 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.120 |
Why?
| | E1A-Associated p300 Protein | 1 | 2016 | 13 | 0.120 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 509 | 0.120 |
Why?
| | Cell Movement | 3 | 2020 | 965 | 0.120 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2016 | 84 | 0.120 |
Why?
| | Metalloporphyrins | 1 | 2016 | 66 | 0.120 |
Why?
| | Glutathione Peroxidase | 2 | 2006 | 39 | 0.110 |
Why?
| | Mitochondria | 4 | 2006 | 984 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.110 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 145 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
| | Ultraviolet Rays | 2 | 2009 | 388 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 983 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 82 | 0.110 |
Why?
| | Female | 16 | 2025 | 78376 | 0.110 |
Why?
| | Up-Regulation | 3 | 2016 | 852 | 0.110 |
Why?
| | DNA Methylation | 3 | 2021 | 683 | 0.100 |
Why?
| | CRISPR-Cas Systems | 2 | 2025 | 170 | 0.100 |
Why?
| | Neural Stem Cells | 2 | 2012 | 166 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2016 | 266 | 0.100 |
Why?
| | Survival Rate | 2 | 2020 | 2092 | 0.100 |
Why?
| | Signal Transduction | 5 | 2025 | 5233 | 0.100 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 477 | 0.100 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 27 | 0.100 |
Why?
| | Cathepsin B | 1 | 2012 | 16 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 31 | 0.090 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 56 | 0.090 |
Why?
| | Prognosis | 3 | 2020 | 4293 | 0.090 |
Why?
| | Aurora Kinases | 1 | 2012 | 28 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 152 | 0.090 |
Why?
| | Early Growth Response Protein 1 | 1 | 2011 | 32 | 0.090 |
Why?
| | Aurora Kinase A | 1 | 2012 | 62 | 0.090 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 79 | 0.090 |
Why?
| | RNA Polymerase II | 2 | 2025 | 351 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 173 | 0.080 |
Why?
| | Dioxygenases | 1 | 2011 | 36 | 0.080 |
Why?
| | Breast | 2 | 2008 | 159 | 0.080 |
Why?
| | Cyclin D1 | 2 | 2008 | 62 | 0.080 |
Why?
| | CpG Islands | 1 | 2011 | 165 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 683 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 309 | 0.080 |
Why?
| | Halogenated Diphenyl Ethers | 1 | 2009 | 7 | 0.070 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 191 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 550 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2016 | 1500 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 444 | 0.070 |
Why?
| | Polychlorinated Biphenyls | 1 | 2008 | 11 | 0.070 |
Why?
| | Carrier Proteins | 1 | 2012 | 737 | 0.070 |
Why?
| | Brain | 3 | 2023 | 2941 | 0.070 |
Why?
| | Tumor Stem Cell Assay | 2 | 2006 | 34 | 0.070 |
Why?
| | Cell Hypoxia | 2 | 2008 | 247 | 0.070 |
Why?
| | Male | 11 | 2021 | 72406 | 0.070 |
Why?
| | Quinazolines | 2 | 2022 | 266 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 627 | 0.070 |
Why?
| | Transfection | 3 | 2019 | 940 | 0.060 |
Why?
| | Hypoxia | 2 | 2011 | 1199 | 0.060 |
Why?
| | Dicumarol | 1 | 2006 | 3 | 0.060 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 183 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2191 | 0.060 |
Why?
| | Electron Spin Resonance Spectroscopy | 4 | 2008 | 97 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2007 | 139 | 0.060 |
Why?
| | Transcription Factor AP-2 | 1 | 2006 | 82 | 0.060 |
Why?
| | G2 Phase | 1 | 2006 | 39 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2012 | 936 | 0.060 |
Why?
| | Cells, Cultured | 5 | 2016 | 4155 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | Mouth Neoplasms | 1 | 2006 | 90 | 0.060 |
Why?
| | Keratinocytes | 1 | 2006 | 250 | 0.060 |
Why?
| | Ubiquitination | 1 | 2025 | 118 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2008 | 1126 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2025 | 56 | 0.050 |
Why?
| | Transcriptome | 2 | 2022 | 1046 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2004 | 14 | 0.050 |
Why?
| | Phosphorylation | 2 | 2020 | 1733 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1980 | 0.050 |
Why?
| | Oxygen | 2 | 2012 | 995 | 0.050 |
Why?
| | Phenotype | 1 | 2012 | 3164 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2004 | 160 | 0.050 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2004 | 98 | 0.050 |
Why?
| | DNA Damage | 2 | 2017 | 430 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 685 | 0.050 |
Why?
| | Membrane Potentials | 1 | 2004 | 280 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 132 | 0.050 |
Why?
| | Androgens | 1 | 2005 | 186 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 222 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 229 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 557 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 168 | 0.050 |
Why?
| | Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 451 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 73 | 0.040 |
Why?
| | Gene Ontology | 1 | 2021 | 54 | 0.040 |
Why?
| | Hot Temperature | 1 | 2004 | 407 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 108 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2006 | 642 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2017 | 383 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2032 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 368 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 460 | 0.040 |
Why?
| | Oxidation-Reduction | 3 | 2011 | 1087 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2021 | 307 | 0.040 |
Why?
| | Oxidative Stress | 4 | 2011 | 1339 | 0.040 |
Why?
| | Biopsy | 1 | 2023 | 1077 | 0.040 |
Why?
| | Time Factors | 3 | 2006 | 7183 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 337 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Kinetics | 3 | 2008 | 1629 | 0.040 |
Why?
| | Airway Resistance | 1 | 1999 | 38 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
| | RNA Interference | 2 | 2012 | 476 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 142 | 0.030 |
Why?
| | Pancreatic Neoplasms | 1 | 2006 | 927 | 0.030 |
Why?
| | Pneumonia | 1 | 2004 | 631 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 63 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 735 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 139 | 0.030 |
Why?
| | Fibroblasts | 3 | 2008 | 1034 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 1026 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5965 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 224 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| | Enzyme Repression | 1 | 2016 | 6 | 0.030 |
Why?
| | Breast Neoplasms | 3 | 2006 | 2456 | 0.030 |
Why?
| | Radiation-Protective Agents | 1 | 2016 | 17 | 0.030 |
Why?
| | Urea | 1 | 2016 | 84 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 128 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2012 | 1173 | 0.030 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 140 | 0.030 |
Why?
| | Electron Transport | 2 | 2006 | 118 | 0.030 |
Why?
| | Adolescent | 5 | 2021 | 22453 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 256 | 0.030 |
Why?
| | Mitosis | 1 | 2016 | 200 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2884 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 326 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 375 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 357 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 650 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1982 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2185 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 769 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 220 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2006 | 269 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Glutathione | 2 | 2006 | 375 | 0.020 |
Why?
| | Glucose | 2 | 2012 | 1049 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 452 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 695 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 140 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2012 | 95 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 14126 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 116 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2882 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4564 | 0.020 |
Why?
| | Genome, Human | 1 | 2014 | 422 | 0.020 |
Why?
| | Antioxidants | 2 | 2005 | 549 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 232 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 147 | 0.020 |
Why?
| | Extracellular Space | 1 | 2011 | 120 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 187 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1490 | 0.020 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2011 | 21 | 0.020 |
Why?
| | Adenosine | 1 | 2012 | 255 | 0.020 |
Why?
| | Mammals | 1 | 2012 | 293 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 205 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2011 | 311 | 0.020 |
Why?
| | Spin Labels | 1 | 2009 | 59 | 0.020 |
Why?
| | Cattle | 1 | 2011 | 1000 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 902 | 0.020 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2008 | 8 | 0.020 |
Why?
| | Photochemistry | 1 | 2009 | 134 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 836 | 0.020 |
Why?
| | Cyclin B1 | 1 | 2008 | 5 | 0.020 |
Why?
| | Cyclin B | 1 | 2008 | 16 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 605 | 0.020 |
Why?
| | Immunoblotting | 1 | 2008 | 300 | 0.020 |
Why?
| | Dicarbethoxydihydrocollidine | 1 | 2007 | 1 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 970 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5614 | 0.020 |
Why?
| | G1 Phase | 1 | 2007 | 66 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 148 | 0.020 |
Why?
| | Uncoupling Agents | 1 | 2006 | 4 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1619 | 0.020 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2006 | 34 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2006 | 32 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1958 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2006 | 79 | 0.020 |
Why?
| | Ceramides | 1 | 2006 | 116 | 0.010 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 26 | 0.010 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1134 | 0.010 |
Why?
| | Chronic Disease | 1 | 2011 | 1813 | 0.010 |
Why?
| | RNA | 1 | 2012 | 940 | 0.010 |
Why?
| | Antimycin A | 1 | 2004 | 14 | 0.010 |
Why?
| | Glutathione Reductase | 1 | 2004 | 25 | 0.010 |
Why?
| | Rotenone | 1 | 2004 | 16 | 0.010 |
Why?
| | NADP | 1 | 2004 | 55 | 0.010 |
Why?
| | Manganese | 1 | 2004 | 55 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3608 | 0.010 |
Why?
| | Oxidants | 1 | 2004 | 103 | 0.010 |
Why?
| | Electrons | 1 | 2004 | 88 | 0.010 |
Why?
| | Amitrole | 1 | 2004 | 9 | 0.010 |
Why?
| | Thiazoles | 1 | 2004 | 136 | 0.010 |
Why?
| | Osteosarcoma | 1 | 2004 | 76 | 0.010 |
Why?
| | Methacrylates | 1 | 2004 | 119 | 0.010 |
Why?
| | Asbestos | 1 | 2004 | 36 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1371 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 266 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 292 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2004 | 498 | 0.010 |
Why?
| | Monocytes | 1 | 2004 | 538 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4569 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 768 | 0.010 |
Why?
| | Unconsciousness | 1 | 1999 | 22 | 0.010 |
Why?
| | Lung Compliance | 1 | 1999 | 42 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1217 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1999 | 43 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2005 | 931 | 0.010 |
Why?
| | Tidal Volume | 1 | 1999 | 111 | 0.010 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 112 | 0.010 |
Why?
| | Adult | 2 | 2016 | 40506 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2002 | 897 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1822 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 1999 | 320 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 35928 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 1999 | 660 | 0.010 |
Why?
| | Lung | 1 | 2004 | 4109 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 6434 | 0.000 |
Why?
| | Infant | 1 | 1999 | 10039 | 0.000 |
Why?
|
|
Venkataraman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|